Current comprehensive assessment and management of women at increased risk for breast cancer

American Journal of Surgery

Volumn 187, Issue 3, 2004, Pages 349-362

  Hollingsworth, Alan B ^a   Singletary, S Eva ^b   Morrow, Monica ^c   Francescatti, Darius S ^d   O'Shaughnessy, Joyce A ^e   Hartman, Anne Renee ^f   Haddad, Becky ^g   Schnabel, Freya R ^h   Vogel, Victor G ⁱ  

^a Mercy Health Center   (United States)

^b UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^c NORTHWESTERN UNIVERSITY   (United States)

^d RUSH MEDICAL COLLEGE   (United States)

^e BAYLOR UNIVERSITY MEDICAL CENTER   (United States)

^f HARVARD MEDICAL SCHOOL   (United States)

^g Susan G Komen Breast Cancer Found   (United States)

^h Department of Orthopaedic Surgery   (United States)

ⁱ UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

Author keywords

Breast cancer; Chemoprevention; Ductal lavage; Hormone replacement therapy; Magnetic resonance imaging; Risk assessment; Risk management strategy

Indexed keywords

AROMATASE INHIBITOR; BRCA1 PROTEIN; BRCA2 PROTEIN; CONJUGATED ESTROGEN; ESTROGEN; ESTROGEN RECEPTOR; GESTAGEN; MEDROXYPROGESTERONE ACETATE; PROGESTERONE; PROGESTERONE RECEPTOR; RALOXIFENE; SELECTIVE ESTROGEN RECEPTOR MODULATOR; TAMOXIFEN;

BREAST BIOPSY; BREAST CANCER; BREAST CARCINOGENESIS; BREAST SURGERY; CANCER EPIDEMIOLOGY; CANCER PREVENTION; CANCER RISK; CANCER SCREENING; CANCER SURGERY; CARDIOVASCULAR DISEASE; CHEMOPROPHYLAXIS; CLINICAL EXAMINATION; CLINICAL PROTOCOL; CLINICAL TRIAL; CYTOLOGY; DIAGNOSTIC IMAGING; FAMILY HISTORY; GENE MUTATION; GENETIC COUNSELING; GENETIC RISK; GENETIC SUSCEPTIBILITY; HIGH RISK POPULATION; HORMONE SUBSTITUTION; HUMAN; LAVAGE; MAINTENANCE THERAPY; MAMMOGRAPHY; MASTECTOMY; MODEL; NUCLEAR MAGNETIC RESONANCE IMAGING; OSTEOPOROSIS; OVARIECTOMY; OVARY CANCER; PATIENT CARE; PATIENT SELECTION; POSTMENOPAUSE; PRIORITY JOURNAL; QUANTITATIVE ANALYSIS; REVIEW; RISK ASSESSMENT; RISK BENEFIT ANALYSIS; RISK FACTOR; RISK MANAGEMENT; RISK REDUCTION; TREATMENT INDICATION; TUMOR BIOPSY;

ADULT; AGE DISTRIBUTION; AGED; ANTINEOPLASTIC AGENTS, HORMONAL; BIOPSY, NEEDLE; BREAST NEOPLASMS; CHEMOTHERAPY, ADJUVANT; COMBINED MODALITY THERAPY; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; INCIDENCE; MASTECTOMY; MIDDLE AGED; NEOPLASM STAGING; PROGNOSIS; RADIOTHERAPY, ADJUVANT; RISK ASSESSMENT; SURVIVAL ANALYSIS; TREATMENT OUTCOME; UNITED STATES;

EID: 1542344996     PISSN: 00029610     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.amjsurg.2003.12.025     Document Type: Review

References (83)

1. Fisher B., Costantino J.P., Wickerham D.L., et al. Tamoxifen for prevention of breast cancer report of the National Surgical Adjuvant Breast and Bowel Project P-1 study. J Natl Cancer Inst. 90:1998;1371-1388.
2. Hartmann L.C., Schaid D.J., Woods J.E., et al. Efficacy of bilateral prophylactic mastectomy in women with a family history of breast cancer. N Engl J Med. 340:1999;77-84.
3. Rebbeck T.R. Prophylactic oophorectomy in BRCA1 and BRCA2 mutation carriers. J Clin Oncol. 18:(suppl):2000;100-103.
4. Grann V.R., Jacobson J.S., Thomason D., et al. Effect of prevention strategies on survival and quality-adjusted survival of women with BRCA 1/2 mutations an updated decision analysis. J Clin Oncol. 20:2002;2520-2529.
5. O'Shaughnessy J.A., Ljung B.M., Dooley W.C., et al. Ductal lavage and the clinical management of women at high risk for breast carcinoma. Cancer. 94:2002;292-298.
6. Brinton L.A., Schairer C., Hoover R.N., Fraumeni J.F. Menstrual factors and risk of breast cancer. Cancer Investigation. 6:1988;245-254.
7. Trichopoulos D., MacMahon B., Cole P. Menopause and breast cancer risk. J Natl Cancer Inst. 48:1972;605-613.
8. Ursin G., Tseng C.-C., Paganini-Hill A., et al. Does menopausal hormone replacement therapy interact with known factors to increase risk of breast cancer? J Clin Oncol. 20:1992;699-706.
9. Tretli S. Height and weight in relation to breast cancer morbidity and mortality a prospective study of 570,000 women in Norway. Int J Cancer. 44:1989;23-30.
10. Longnecker M.P., Berlin J.A., Orza M.J., Chalmers T.C. A meta-analysis of alcohol consumption in relation to risk of breast cancer. JAMA. 260:1988;652-656.
11. Sattin R.W., Rubin G.L., Webster L.A., et al. Family history and the risk of breast cancer. JAMA. 253:1985;1908-1913.
12. Gail M.H., Brinton L.A., Byar D.P., et al. Projecting individualized probabilities of developing breast cancer for white females who are being examined annually. J Natl Cancer Inst. 81:1989;1879-1886.
13. Sharpe C.R. A development hypothesis to explain the multicentricity of breast cancer. Can Med Assoc J. 159:1998;55-59.
14. Clemons M., Loijens L., Goss P. Breast cancer risk following irradiation for Hodgkin's disease. Cancer Treat Rev. 26:2000;291-302.
15. Page DL, Dupont WD, Rogers LW, Landenberger M. Intraductal carcinoma of the breast: follow-up after biopsy only. Cancer 1982;751-8.
16. Hutter R.V. The management of patients with lobular carcinoma in situ of the breast. Cancer. 53:1984;2-798.
17. Singletary S.E. A working model for the time sequence of genetic changes in breast tumorigenesis. J Am Coll Surg. 194:2002;202-216.
18. Dupont W.D., Page D.L. Risk factors for breast cancer in women with proliferative breast disease. N Engl J Med. 312:1985;146-151.
19. Wrensch M.R., Petrakis N.L., King E.B., et al. Breast cancer incidence in women with abnormal cytology in nipple aspirates of breast fluid. Am J Epidemiol. 135:1992;130-141.
20. Fabian C.J., Kimler B.F., Zalles C.M., et al. Short-term breast cancer prediction by random periareolar fine-needle aspiration cytology and the Gail risk model. J Natl Cancer Inst. 92:2000;1217-1227.
21. King E.B., Chew K.L., Petrakis N.L., Ernster V.L. Nipple aspirate cytology for the study of breast cancer precursors. J Natl Cancer Inst. 71:1983;1115-1121.
22. Krishnamurthy S, Sneige N, Thompson PA, et al. Nipple aspirate fluid cytology in breast cancer. Cancer 2003;99:97-104.
23. Keating N.L., Cleary P.D., Rossi A.S., et al. Use of hormone replacement therapy by postmenopausal women in the United States. Ann Intern Med. 130:1999;545-553.
24. Collaborative Group on Hormonal Factors in Breast Cancer. Breast cancer and hormone replacement therapy collaborative reanalysis of data from 51 epidemiological studies of 52,705 women with breast cancer and 108,411 women without breast cancer. Lancet. 350:1997;1047-1059.
25. Schairer C., Lubin J., Troisi S., et al. Menopausal estrogen and estrogen-progestin replacement therapy and breast cancer risk. JAMA. 283:2000;485-491.
26. Ross R.K., Paganini-Hill A., Wan P.C., Pike N.C. Effect of hormone replacement therapy on breast cancer risk estrogen versus estrogen plus progestin. J Natl Cancer Inst. 92:2000;328-332.
27. Writing Group for the Women's Health Initiative Investigators. Risks and benefits of estrogen plus progestin in healthy postmenopausal women. Principal results from the Women's Health Initiative randomized controlled trial. JAMA. 288:2002;321-333.
28. Gapstur S.M., Morrow M., Sellers T.A. Hormone replacement therapy and breast cancer with a favorable pathology. JAMA. 281:1999;2091-2097.
29. Jordan V.C., Morrow M. Editorial. Raloxifene as a multifunctional medicine? BMJ. 319:1999;331-332.
30. Vogel V.G. Assessing potential risk of developing breast cancer. Oncology. 10:1996;1451-1461.
31. London S.J., Connolly J.L., Schnitt S.J., et al. A prospective study of benign breast disease and the risk of breast cancer. JAMA. 267:1992;941-944.
32. Vogel V.G. High-risk populations as targets for breast cancer prevention trials. Prev Med. 20:1991;86-100.
33. Costantino J.P., Gail M.H., Pee D., et al. Validation studies for models projecting the risk of invasive and total breast cancer incidence. J Natl Cancer Inst. 91:1999;1541-1548.
34. Bondy M.L., Lustbader E.D., Halabi S., et al. Validation of a breast cancer risk assessment model in women with a positive family history. J Natl Cancer Inst. 86:1994;620-625.
35. Claus E., Risch N., Thompson W.D. The calculation of breast cancer risk for women with a first degree family history of ovarian cancer. Breast Cancer Res Treat. 28:1993;115-120.
36. Rockhill B., Spiegelman D., Byrne C., et al. Validation of the Gail et al model of breast cancer risk prediction and implications for chemoprevention. J Natl Cancer Inst. 93:2001;358-366.
37. Claus E.B., Risch N., Thompson W.D. Autosomal dominant inheritance of early-onset breast cancer. Implications for risk prediction. Cancer. 73:1994;643-651.
38. Couch F.J., DeShano M.L., Blackwood A., et al. BRCA1 mutations in women attending clinics that evaluate the risk of breast cancer. N Engl J Med. 336:1997;1409-1415.
39. Shattuck-Eidens D., McClure M., Simard J., et al. A collaborative survey of 80 mutations in the BRCA1 breast and ovarian cancer susceptibility gene implications for presymptomatic testing and screening. JAMA. 273:1995;535-541.
40. Frank T.S., Deffenbaugh A.M., Hulick M., et al. Hereditary susceptibility to breast cancer significance of age of onset in family history and contribution of BRCA1 and BRCA2. Dis Markers. 15:1999;89-92.
41. Berry D.A., Iversen E.S., Gudbjartsson D.F., et al. BRCAPRO validation, sensitivity of genetic testing of BRCA1/BRCA2, and prevalence of other breast cancer susceptibility genes. J. Clin Oncol. 20:2002;2701-2712.
42. Vogel VG, editor. Management of Patients at High Risk for Breast Cancer. Malden, MA: Blackwell Science, 2001.
43. Wellings S.R. A hypothesis of the origin of human breast cancer from the terminal ductal lobular unit. Pathol Res Pract. 166:1980;515-535.
44. Hutchinson W.B., Thomas D.B., Hamlin W.B., et al. Risk of breast cancer in women with benign breast disease. J Natl Cancer Inst. 65:1980;13-20.
45. Dooley W.C., Ljung B.M., Veronesi U., et al. Ductal lavage for detection of cellular atypia in women at high risk for breast cancer. J Natl Cancer Inst. 93:2001;1624-1632.
46. Petricoin E.F., Ornstein D.K., Paweletz C.P., et al. Serum proteomic patterns for detection of prostate cancer. J Natl Cancer Inst. 94:2002;1576-1578.
47. Morrow M., Vogel V., Ljung B.M., O'Shaughnessy J.A. Evaluation and management of the woman with an abnormal ductal lavage. J Am Coll Surg. 194:2002;648-656.
48. Page D.L., Dupont W.D., Rogers L.W., et al. Atypical hyperplastic lesions of the female breast a long-term follow-up study. Cancer. 55:1985;2698-2708.
49. Wrensch M.R., Petrakis N.L., Miike R., et al. Breast cancer risk in women with abnormal cytology in nipple aspirates of breast fluid. J Natl Cancer Inst. 93:2001;1791-1798.
50. Colditz G.A., Rosner B. Cumulative risk of breast cancer to age 70 years according to factor status data from the Nurses' Health Study. Am J Epidemiol. 152:2000;950-964.
51. Fisher B., Dignam J., Wolmark N., et al. Tamoxifen in treatment of intraductal breast cancer National Surgical Adjuvant Breast and Bowel Project B-24 randomized controlled trial. Lancet. 353:1999;1993-2000.
52. Fisher B., Costantino J., Redmond C., et al. A randomized clinical trial evaluating tamoxifen in the treatment of patients with node-negative breast cancer who have estrogen-receptor-positive tumors. N Engl J Med. 320:1989;479-484.
53. Easton D.F., Ford B.P., Bishop D.T., Breast Cancer Linkage Consortium. Breast and ovarian cancer incidence in BRCA1-mutation carriers. Am J Hum Genet. 56:1995;265-271.
54. van Leeuwen F.E., Klokman W.J., Hagenbeek A., et al. Second cancer risk following Hodgkin's disease a 20-year follow-up study. J Clin Oncol. 12:1994;312-325.
55. Smith R.A., Cokkinides V., von Eschenbach A.C., et al. American Cancer Society guidelines for the early detection of cancer. CA Cancer J Clin. 52:2002;8-22.
56. Cummings S.R., Eckert S., Krueger K.A., et al. The effect of raloxifene on risk of breast cancer in postmenopausal women. Results from the MORE randomized trial. JAMA. 281:1999;2189-2197.
57. Vogel VG, Costantino JP, Wickerham DL, et al. The study of tamoxifen and raloxifene: preliminary enrollment data from a randomized breast cancer risk reduction trial. Clin Breast Cancer 2002;3:153-9.
58. Chlebowski R.T., Col N., Winer E.P., et al. American Society of Clinical Oncology technology assessment of pharmacologic interventions for breast cancer risk reduction including tamoxifen, raloxifene, and aromatase inhibition. J Clin Oncol. 20:2002;3328-3343.
59. Fletcher S.W., Colditz G.A. Failure of estrogen plus progestin therapy for prevention. JAMA. 288:2002;366-368.
60. Eisen A., Rebbeck T.R., Wood W.C., Weber B.L. Prophylactic surgery in women with a hereditary predisposition to breast and ovarian cancer. J Clin Oncol. 18:2000;1980-1995.
61. Kinsinger L.S., Harris R., Woolf S.H., et al. Chemoprevention of breast cancer a summary of the evidence for the U.S. Prevention Services Task Force. Ann Intern Med. 137:2002;59-67.
62. King M.C., Wieand S., Hale K., et al. Tamoxifen and breast cancer incidence among women with inherited mutations in BRCA1 and BRCA2 National Surgical Adjuvant Breast and Bowel Project (NSABP-P1) breast cancer prevention trial. JAMA. 286:2001;2251-2256.
63. Narod S.A., Brunet J.S., Gharirian P., et al. Tamoxifen and risk of contralateral breast cancer in BRCA1 and BRCA2 mutation carriers a case control study. Hereditary Breast Cancer Clinical Study Group. Lancet. 356:2000;1876-1881.
64. Kauff N.D., Satagopan J.M., Robson M.E., et al. Risk-reducing salpingo-oophorectomy in women with a BRCA1 or BRCA2 mutation. N Engl J Med. 346:2002;1609-1615.
65. Rebbeck T.R., Lynch H.T., Neuhausen S.L., et al. Prophylactic oophorectomy in carriers of BRCA1 or BRCA2 mutations. N Engl J Med. 346:2002;1616-1622.
66. Weinreb J.C., Newstead G. MR imaging of the breast. Radiology. 196:1995;593-610.
67. Harms S.E. Breast magnetic resonance imaging. Semin Ultra-sound CT MR. 19:1998;104-120.
68. Lynch H.T., Albano W.A., Danes B.S., et al. Genetic predisposition to breast cancer. Cancer. 53:1984;612-622.
69. Ford D., Easton D.F., Stratton M., et al. Genetic heterogeneity and penetrance analysis of the BRCA1 and BRCA2 genes in breast cancer families. Am J Hum Genet. 62:1998;676-689.
70. Struewing J.P., Hartage P., Wacholder S., et al. The risk of cancer associated with specific mutations of BRCA1 and BRCA2 among Ashkenazi Jews. N Engl J Med. 336:1997;1401-1408.
71. Schrag D., Kuntz K.M., Garber J.E., Weeks J.C. Decision analysis - effects of prophylactic mastectomy and oophorectomy on life expectancy among women with BRCA1 or BRCA2 mutations. N Engl J Med. 336:1997;1465-1471.
72. Hartmann L.C., Sellers T.A., Schaid D.J., et al. Efficacy of bilateral prophylactic mastectomy in BRCA1 and BRCA2 gene mutation carriers. J Natl Cancer Inst. 93:2001;1633-1637.
73. Harms S.E., Flamig D.P. MR imaging of the breast. J Magn Reson Imaging. 3:1993;277-283.
74. Kaiser W.A., Zeitler E. MR imaging of the breast fast imaging sequences with and without Gd-DTPA. Preliminary observations. Radiology. 170:1989;681-686.
75. Orel S.G., Schnall M.D., Powell C.M., et al. Staging of suspected breast cancer effect of MR imaging and MR-guided biopsy. Radiology. 196:1995;115-122.
76. Tilanus-Linthorst M.M., Obdeijn I.M., Bartels K.C., et al. First experiences in screening women at high risk for breast cancer with MR imaging. Breast Cancer Res Treat. 63:2000;53-60.
77. Kuhl C.K., Schmutzler R.K., Leutner C.C., et al. Breast MR imaging screening in 192 women proved or suspected to be carriers of a breast cancer susceptibility gene preliminary results. Radiology. 215:2000;267-279.
78. Brown J., Buckley D., Coulthard A., et al. Magnetic resonance imaging screening in women at genetic risk of breast cancer imaging and analysis protocol for the UK multicentre study. UK MRI breast Screening Study Advisory Group. Magn Reson Imaging. 18:2000;765-776.
79. Warner E., Plewes D.B., Shumak R.S., et al. Comparison of breast magnetic resonance imaging, mammography, and ultrasound for surveillance of women at high risk for hereditary breast cancer. J Clin Oncol. 19:2001;3524-3531.
80. Stoutjesdijk M.J., Boetes C., Jager G.J., et al. Magnetic resonance imaging and mammography in women with a hereditary risk of breast cancer. J Natl Cancer Inst. 93:2001;1095-1102.
81. Warner E., Plewes D.B., Hill K., et al. Three year results of annual breast magnetic resonance imaging (MRI) and ultrasound (US) in addition to mammography and clinical breast examination for surveillance of women at high risk for hereditary breast cancer. Proc Am Soc Clin Oncol. 21:2002;1704.
82. Prochaska J.O. Treating entire populations for behavior risks for cancer. Cancer J. 7:2001;360-368.
83. Vogel V.G., Costantino J.P., Wickerham D.L., Cronin W.M. Tamoxifen for prevention of breast cancer report of the National Surgical Adjuvant Breast and Bowel Project P-1 study. J Natl Cancer Inst. 94:2002;1504.